You are here: Home » Companies » News
Business Standard

Zydus launches affordable diabetic drug Tenglyn

Drug-maker wants to make this important therapy affordable and accessible to diabetic patients

BS Reporter  |  Ahmedabad 

Zydus launches affordable diabetic drug Tenglyn

Ahmedabad-based Zydus Cadila launched Tenglyn - Teneligliptin 20 mg tablets, which belongs to a new class of oral anti-diabetic agents, Gliptins. Zydus claimed that with an aim to make this important therapy affordable and accessible to diabetic patients, Tenglyn is being priced at Rs 7 per tablet which is almost one-sixth the price at which the Gliptins were initially launched in India.

Gliptins have shown promise in achieving glycemic control without deteriorating beta cell function and is one of the most recent advancements in diabetes care and management.

Speaking on the development, Sharvil Patel, deputy managing director, Zydus Cadila, said, "Diabetes, as we know, is becoming a major health burden globally. We remain committed to this fight against diabetes and with Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost." The number of diabetics in the world is estimated to be over 360 million.

With a patient population of almost 65 million diabetics in India, access to affordable therapy is critical.

The group had earlier launched Lipaglyn (Saroglitazar), for the treatment of diabetic dyslipidemia and hypertriglyceridemia. It has over 20 discovery programmes in the areas of diabetes and other cardio-metabolic disorders.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, November 20 2015. 17:10 IST